Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio.
Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes :
Each theme is rated taking into account several comprehensive sub-categories.
Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter. Indeed, our process is supported by a network of local experts that have a deep knowledge of each local market best practices (from both customs and regulatory points of views).
If you are interested in the Proxinvest Corporate Governance Rating ®, please contact directly Proxinvest ( or +33(0)1 45 51 50 43).
Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
SES (Achat hybrides) : L’incertitude sur le produit C-Band crée une opportunité d’Achat (+) Uniqa (Achat) - 9M-19 : Résultat avant impôts de €215m (+2,4%) Alpha Bank : Va titriser €12 mds de prêts douteux Ageas (Achat) : Rachat (Tender) des titres FRESH (AGSBB Float PERP) à un prix 59% Teva (Achat) : Emission de $2,1mds d’obligations senior à maturité 2025 Aldesa (Vente) : China Railway serait intéressé pour acquérir une participation majoritaire Stryker Corporation : Emission d’obligations de maturité 5 ans, 9 ans et 12 ans M...
Merck KGaA (O/P): Raises Its 2019 Targets SEB - Skandinaviska Enskilda Banken (O/P): Investigation of Money Laundering Cases Grand City Properties (M/P) - 9M-19: EBITDA of €220.0m (+8%) OHL (U/P) - 9M-19: EBITDA of €40m (Compared To -€468m On 9M-18) Icade (M/P): Acquisition of Confluent Group For €194m Volkswagen (O/P): Investment Plan of Nearly €60bn Over 5 Years (2020-2024) Saipem (O/P): Considers A Merger With Its Norwegian Competitor Subsea 7 Fitch Affirms The Ratings of Intesa Sanpaolo (O/P), Unicredit (O/P) And UBI Banca ...
Merck KGaA (Achat) : Relèvement des objectifs 2019 SEB (Achat) : Enquête sur des affaires de blanchiment d'argent Grand City Properties (Conserver) - 9M-19 : EBITDA de €220,0m (+8%) OHL (Vente) - 9M-19 : EBITDA de €40m (contre -€468m sur les 9M-18) Icade (Conserver) : Acquisition du Groupe Confluent pour €194m Volkswagen (Achat) : Plan d’investissements de près de €60 mds sur 5 ans (2020-2024) Saipem (Achat) : Considère une fusion avec son concurrent norvégien Subsea 7 Fitch confirme les notes d'Intesa SanPaola (Achat), UniCredi...
In general, Argenx is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting. Under ITEM 3, the board of directors seeks approval to amend the Company’s stock option plan ("the Plan"). Although ECGS has no (major) concerns over the proposed amendments, it notes that Plan allows for a (potential) aggregate capital increase of 14.5% of the Company’s issued share capital, which exceeds ECGS’guidelines. In addition, ECGS considers the vesting period for time vesting awards (of between 1 and 3 years) too short. Based on the above, ...
In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEMS 4 and 5.2 the board of directors seeks approval for the Company's remuneration report (ITEM 4) and remuneration policy (ITEM 5.2). Although ECGS strongly welcomes the first separate remuneration report, Coloplast's remuneration structure is NOT considered to be in line with its guidelines. Accordingly, ECGS recommends to vote OPPOSE to both agenda items. Under ITEM 6.1 it is proposed to (re-)appoint Mr. Lars Søren Rasmussen as Chairman of ...
In general, Adyen is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting. Under ITEM 2, the supervisory board proposes to newly appoint Ms. Mariëtte Bianca Swart as the Company's Chief Legal and Compliance Officer (CLCO) and member of the executive board for a period of 4-years. ECGS has no concerns over Ms. Swart’s appointment and accordingly recommends to vote FOR. Under ITEM 3, the supervisory board proposes to newly appoint Mr. Kamran Zaki as Adyen's Chief Operating Officer (COO) and member of the executive board for a...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.